Literature DB >> 8534861

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.

O V Volpert1, V Stellmach, N Bouck.   

Abstract

Fifteen different natural inhibitors of angiogenesis have now been identified that are produced by mammalian cells and are able to block in vivo neovascularization. The majority of these are able to inhibit endothelial cell activities in vitro and all those tested have demonstrated significant antitumor activity. Most normal cells produce inhibitors of neovascularization that must be downregulated before the cells can develop into angiogenic, malignant tumors. In several cases the production of inhibitors ceases when tumor suppressor genes are inactivated. In the BT549 human breast carcinoma cell line, the reintroduction of a wild type p53 tumor suppressor gene resulted in the stimulation of the secretion of an inhibitor of angiogenesis, thrombospondin-1, and as a result the cells lost their angiogenic phenotype and became able to suppress angiogenesis induced by the parental tumor line. These results provide a new example of tumor suppressor gene control of a natural inhibitor of angiogenesis and add support to the concept that thrombospondin loss may play an important role in the development of some human breast cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534861     DOI: 10.1007/bf00666034

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  52 in total

1.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro.

Authors:  M L Iruela-Arispe; P Bornstein; H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells.

Authors:  E G Van Meir; P J Polverini; V R Chazin; H J Su Huang; N de Tribolet; W K Cavenee
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

3.  Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.

Authors:  J A Eisman; D H Barkla; P J Tutton
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

4.  Interleukin 1 is an autocrine regulator of human endothelial cell growth.

Authors:  F Cozzolino; M Torcia; D Aldinucci; M Ziche; F Almerigogna; D Bani; D M Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Specific inhibition of endothelial cell proliferation by thrombospondin.

Authors:  P Bagavandoss; J W Wilks
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

6.  Differential effects of interferon gamma and alpha on in vitro model of angiogenesis.

Authors:  R K Maheshwari; V Srikantan; D Bhartiya; H K Kleinman; D S Grant
Journal:  J Cell Physiol       Date:  1991-01       Impact factor: 6.384

7.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation.

Authors:  A N Murphy; E J Unsworth; W G Stetler-Stevenson
Journal:  J Cell Physiol       Date:  1993-11       Impact factor: 6.384

9.  Inhibition of angiogenesis through modulation of collagen metabolism.

Authors:  D Ingber; J Folkman
Journal:  Lab Invest       Date:  1988-07       Impact factor: 5.662

10.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.

Authors:  M D Johnson; H R Kim; L Chesler; G Tsao-Wu; N Bouck; P J Polverini
Journal:  J Cell Physiol       Date:  1994-07       Impact factor: 6.384

View more
  17 in total

1.  A novel in vitro model of tumor angiogenesis.

Authors:  D Kozien; M Gerol; B Hendey; A RayChaudhury
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-10       Impact factor: 2.416

2.  Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.

Authors:  M Watanabe; K L McCormick; K Volker; J R Ortaldo; J M Wigginton; M J Brunda; R H Wiltrout; W E Fogler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 3.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

Review 4.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

Review 5.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.

Authors:  P S Steeg; S E Clare; J A Lawrence; Q Zhou
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 6.  Angiogenesis in transgenic models of multistep carcinogenesis.

Authors:  M G D' Angelo; T Afanasieva; A Aguzzi
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

7.  Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.

Authors:  J Lawler; W M Miao; M Duquette; N Bouck; R T Bronson; R O Hynes
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 8.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

9.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis.

Authors:  Marie M Krady; Jianmin Zeng; Jun Yu; Susan MacLauchlan; Eleni A Skokos; Weiming Tian; Paul Bornstein; William C Sessa; Themis R Kyriakides
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

10.  Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.

Authors:  S L Maloney; D C Sullivan; S Suchting; J M J Herbert; E M Rabai; Z Nagy; J Barker; S Sundar; R Bicknell
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.